ERBB2 and breast cancer: ErbB2-positive (HER2/neu) breast cancer cells are usually treated with lapatinib (a dual inhibitor of the EGRF and ERBB2/HER2 tyrosine kinase inhibitor) as a first line monotherapy [92–94].